Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 7/20 | 0.32 |
| ▸ | CTSB | P07858 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111580 | 0.86 | PTGS2 (0.33) | ALDH1A1KDM4EHSD17B10TSHRPTGS2 | |
| SCHEMBL3780098 | 0.82 | CA12 (0.47) | ALDH1A1PTGS2CTSLCTSBKMT2A | |
| SCHEMBL3104766 | 0.81 | ROCK2 (0.38) | ALDH1A1PTGS2RAB9APTGS1SMN1; SMN2 | |
| SCHEMBL3116579 | 0.79 | ALDH1A1 (0.37) | ALDH1A1KDM4EHSD17B10TSHRPTGS2 | |
| SCHEMBL13016815 | 0.79 | ALDH1A1 (0.37) | ALDH1A1KDM4EHSD17B10TSHRPTGS2 | |
| SCHEMBL5973429 | 0.73 | KMT2A (0.39) | PTGS2CTSLCTSBKMT2APTGS1 | |
| SCHEMBL3811407 | 0.72 | CACNA2D1 (0.40) | — | |
| SCHEMBL3118583 | 0.71 | CA1 (0.42) | PTGS2CTSLCTSBKMT2ARAB9A | |
| SCHEMBL3111586 | 0.71 | EGLN2 (0.42) | ALDH1A1KDM4EHSD17B10RAB9AHPGD | |
| SCHEMBL13016806 | 0.71 | EGLN2 (0.42) | ALDH1A1KDM4EHSD17B10RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | claimed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | claimed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| EP-1572627-A1 | DRUGS FOR CHRONIC PAIN | Nicox S.A. (FR) | 2005-09-14 | — | — | EP | claimed |
| WO-2004054965-A1 | DRUGS FOR CHRONIC PAIN | NICOX S.A. (FR) | 2004-07-01 | — | — | WO | claimed |
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7642289-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20060270608-A1 | Drugs for chronic pain | NICOX S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | ALDH1A1 671/4885KDM4E 1944/4885HSD17B10 288/4885 |
| US-20060270608-A1 | Drugs for chronic pain | OPRK1, OPRL1, OPRD1 | ALDH1A1 671/4885KDM4E 1944/4885HSD17B10 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.